
Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part of a phase 1 study …

Flemish biopharma company, Bioxodes, has announced promising results from the BIRCH phase 2a clinical trial of BIOX-101 to treat intracerebral …

Two clinical-stage oncology programmes from Astex Pharmaceuticals have been announced by Mosaic Therapeutics, allowing it to develop targeted oncology drug …
ViroCell Biologics has manufactured a GMP-grade lentiviral vector for a University College London (UCL) clinical trial aimed at tackling relapse …
Pharming Group has announced that the first patient has been dosed in a phase 2 clinical trial evaluating leniolisib in …

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …

Today, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have announced that they are launching a first-of-its-kind clinical trial to …

Camurus has announced positive results from its 52-week phase 3 open-label ACROINNOVA 2 study, which assessed the safety and efficacy …

Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …

iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.

Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction …

NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …

Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has announced that it has initiated the recruitment for its phase 2 REGENERATE-PD …

Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated …

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …